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Abstract
As cancer research continues to move towards more personalized methods,
targeted inhibitors of oncogenic drivers of cancer are found to be an innovative and
promising therapeutic approach. Previously thought to be undruggable regions of the
genome, RNA has become an area of increasing interest in cancer due to the
identification of more targetable regions and their relationship to tumor growth and
progression. This work reports on the development of IACS-13743, a novel small
molecule found to directly bind and inhibit microRNA-10b. Oncogenic miR-10b has
been found to be overexpressed in several malignant cancer types, making it an
attractive biomarker for targeted inhibitor therapy. IACS-13743 is found to impede
tumor progression and proliferation in brain cancer, gastric cancer and pancreatic
cancer in vitro. This effect is also shown in a cerebral organoid model. Using a
multidisciplinary approach, this study identifies a relationship between oncogenic miR10b and the dysregulation of the PI3K/AKT pathway in cancer, along with putting forth
a compound that can mitigate these effects. These findings provide a fundamental
step in moving forward a targeted therapeutic for a known oncogenic RNA driver and
unique biomarker in multiple malignant cancer types.
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Chapter 1. Introduction
RNA therapeutics as an emerging approach
Cancer continues to be a leading health issue worldwide, with an estimated
1,898,160 new cancer incidences and 608,570 deaths projected in the United States
in 20211. As more advanced technologies and therapeutic approaches continue to be
developed, these rates will decrease, although the challenges of tumor heterogeneity,
metastasis and further understanding of the mechanisms of treatment resistance
remain. There are several malignant cancer types through which the common
modalities of surgery, radiation and chemotherapy are not sufficient in yielding antitumor effects, and while promising approaches such as immunotherapy are gaining
traction, there is a need for more innovative methods to target tumors that are
resistant to these existing modalities and for the development of more personalized
approaches. Three such cancer types include brain cancer, gastric cancer, and
pancreatic cancer. There will be approximately 18,600, 11,180, and 48,220 deaths
from these cancers alone in the United States in 2021, with many more patients
diagnosed1. While treatments for these tumor types exist, the life expectancy of each
of these cancers is minimal, due to these increased mechanisms of therapeutic
resistance and inability for early detection until the malignancies become too
advanced for conventional forms of treatment.
Targeted therapeutics are the frontrunner in the pursuit of personalized
medicine. The concept involves designing drugs that are specific to oncogenic cells
or to tissue microenvironments that are conducive to tumor growth and proliferation,
with minimal off-target effects2. A large limitation of existing radiotherapies and
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chemotherapies is the lack of specificity to the target of interest, along with high
degrees of toxicity and potential impacts to long-term quality-of-life. Drug discovery
continues to be a growing field, as advances in technology continue to allow for more
avenues of therapeutic targeting. However, there are two main challenges that are
consistent in creating an effective drug; the first is that the drug has to be able to
arrive at the site of action, taking into consideration lipophilicity and size of the
molecules as they travel throughout the body and its membranes3. The second is that
it must be able to yield a biological effect by modulating its intended target once it
reaches the site of action. This field has long focused on the therapeutic targeting of
proteins, and while this strategy has shown to be effective, identifying nearly 700
therapeutically targetable proteins, only 1.5% of the human genome encodes for
proteins, which leads to only approximately 0.05% of the entire human genome being
successfully targeted4, 5 (Figure 1).

Human genome
Diseaserelated

Targeted by existing
drugs (0.05%)
Difficult to drug as
proteins (10-15%)

Potentially druggable
RNAs (~70%)
Proteins (1.5%)
Figure 1. Diagram portraying the human genome and the potential for
discovery of biomarkers and novel targeted therapeutics. Adapted from
Warner K. D.; Hajdin, C. E.; Weeks, K. M., Principles for targeting RNA with
drug-like small molecules. Nat Rev Drug Discov 2018, 17 (8), 547-558.
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While the central dogma of molecular biology has primarily focused on RNA
as the intermediate transcript through which DNA is translated into proteins, it hasn’t
been until recent decades that the roles of RNA have been further studied and found
to be much more extensive than originally thought6,7. There is the classical subset of
RNAs that are classified as coding, where RNA transcripts are translated into
messenger RNA and eventually become proteins. However, the grand majority of
RNAs are classified as non-coding, which do not undergo translation. Initially thought
to be non-functional because they do not translate to proteins, a multitude of studies
over the years have found forms of RNAs that play significant roles in regulating gene
expression at the transcriptional and post-transcriptional levels. They can either be
overexpressed or repressed and thereby act as biomarkers that can then be
modulated and potentially therapeutically targeted8.
Oncogenic microRNAs, otherwise called oncomiRs, are a class of small noncoding RNAs found to be overexpressed in several tumor types and can directly
target tumor suppressing genes. The overexpression of these specific miRNAs leads
to the targeting of tumor suppressor genes, rendering their function limited or nonfunctional, thereby promoting an oncogenic outcome. By extension, the inhibition of
these miRNAs via a targeted therapeutic approach, inhibiting the overexpressed
oncogenic miRNAs would then allow for normal function of the tumor suppressor
genes (Figure 2).
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Figure 2: miRNAs can serve either oncogenic or tumor suppressive functions.
Shown is a graphical depiction of both circumstances, when the miRNA is
over-expressed, leading to suppression of the tumor suppressor gene, and
when the miRNA is under-expressed, when there is no binding to the mRNA
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There are various approaches that have been developed in the targeting of
overexpressed miRNAs; ultimately the use of anti-sense oligonucleotides and small
molecules have gained the most attention. Oligonucleotides work as competitive
inhibitors in this mechanistic process by blocking the mature miRNA from interacting
with the target mRNAs, allowing for normal functioning of the mRNA7. There are
several limitations of such molecules in translational use, in that oligonucleotides tend
to be larger and can yield off-target effects when the oligonucleotide sequence binds
an RNA with a sequence similar to the target RNA9. Small molecules the other main
group found to target miRNA. They are defined as a class of molecules with lower
molecular weight and have chemical properties such that they are able to diffuse
through membranes into cells much more easily. They are designed to be smaller
and more specific to the target of interest, often with better cellular solubility and
permeability, making it a more practical and viable approach for diffusion through
tissues. Most targeted therapies are composed of small molecules.
The general concept of using small molecules to target overexpressed
miRNAs as a novel therapeutic approach has gained interest in recent years10, along
with the strategies for modeling RNA providing important insights into RNA-small
molecule interactions for drug development and discovery11,
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. Directly targeting

miRNAs with small molecules allows for the functional inhibition of specific miRNAs
that often cannot be achieved through targeting of proteins that are associated with
these miRNAs4. This work will focus on the targeting of a specific oncogenic miRNA
using a novel small molecule inhibitor.
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Oncogenic miR-10b in cancer
Oncogenic miR-10b is a microRNA that has been reported to be involved in
tumor progression by positively regulating cellular migration and invasion pathways
in several cancer pathologies13-18. While it has long been established in cancer
progression, there are several mechanistic pathways that have been theorized to
yield its tumor promoting effects in multiple cancer types. The next subsections will
focus on the role of this specific miRNA in our three cancer types of interest for this
study.

miR-10b in brain cancer
Oncogenic miR-10b has long been established to be upregulated in a cancer
context in the brain microenvironment. Interestingly, this microRNA is typically found
in very low amounts in normal brain cells, but miR-10b is found to be highly
overexpressed in several malignant primary brain tumor types13, 18-21. In a work by
Gabriely et al. (2011), miR-10b expression levels in normal and tumor tissues were
measured, and it was found that starting in low-grade gliomas (Grades 2 and 3), miR10b levels were found to be significantly upregulated as compared to non-cancerous
brain tissue13. This effect was also consistently seen in glioma stem cells in a number
of other studies, where expression levels of miR-10b were as high or higher than in
glioblastoma cell lines and much higher than in normal astrocytes, a common glial
cell of origin for gliomas and glioblastomas19, 20.
There are several proposed mechanisms implicated in this effect and as it is
not highly detected in neuroprogenitor cells, it is proposed that it could serve as a
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biomarker for the induction of gliomagenesis20. In a study by Lin et al., (2012), the
authors investigated the impact of miR-10b as it relates to cellular growth, invasion
and angiogenetic potential. While the study focused on the mesenchymal subtype of
glioblastoma, the authors determined that the invasive potential of glioma cells can
be modulated when silenced, and that miR-10b can play a pleiotropic role, wherein it
is not limited to the mechanisms of cellular growth or apoptosis, but can also include
the functions of invasion and angiogenesis14. In the work by Sun et al., (2019), the
authors identified that miR-10b, together with miR-222, promote gliomagenesis via
the gene PTEN, where both miRNAs were found to target the tumor suppressor gene
and activated the p53 pathway via the suppression of MDM2, leading to cell cycle
arrest and yielding an oncogenic outcome22. In the work by Teplyuk et al, (2016), the
authors focused on establishing the role of miR-10b in glioma stem cells, and found
that this miRNA was found to be implicated in cell cycle and RNA splicing functions
and that its inhibition led to a sharp decrease in tumor cell viability and survival20. In
the work by Ma et al., (2017), they established a link between the TGF-b pathway
and increased rates of proliferation, migration and epithelial-to-mesenchymal
transition (EMT) in glioblastoma through the suppression of a number of its target
genes including PTEN, E-cadherin, and Apaf-123. All of these studies provide
evidence of the roles that miR-10b has been implicated in with regards to tumor
progression in the brain; while the roles may be varied, it is clear there is sufficient
background of establishing this miRNA as oncogenic in the brain context.
Given any number of contextual and cell-specific cues that may activate these
cancer pathways, it is difficult to pin down one specific pathway that may be at play
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when it comes to miR-10b and cancers of the brain, but these studies have served to
provide multiple targetable avenues to therapeutically pursue.

miR-10b in gastric cancer and pancreatic cancer
Gastric cancer is one of the most common cancer malignancies worldwide
generally found to occur sporadically in adults over the age of 45 years with variable
survival rate according to histopathological classification24. While there have been
several studies investigating the presence and impact of miR-10b in this
microenvironment and some discussion about whether this microRNA acts as an
oncogene or tumor suppressor, it is generally accepted that this miRNA contributes
as a driver of cancer. In the study by Li et. al, (2010), the authors identified miR-10b
as one of seven miRNAs that formed a signature correlating miRNA expression
pattern with prognostic outcome. Using this miRNA signature, the study was able to
differentiate between relapse-free survival and progression-free survival in a cohort
of patients, along with using this signature in a predictive context to determine
whether there were differential outcomes. miR-10b was specifically found to be part
of the “risk” miRNAs, where expression levels of this group were correlated with
shorter survival. This study supported the oncogenic role of miR-10b in gastric cancer
and yields insight in stratification and treatment planning for patients with this cancer
type25. In the work by Wang et al., (2013), authors established via RT-PCR that miR10b was highly upregulated in primary gastric cancer tissues as compared to nontumor gastric tissues, and found that a more severe phenotype, one that incorporates
lymph node involvement and distant metastasis, was associated with a higher
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expression level of miR-10b. Additionally, when investigating clinicopathological
outcomes, higher expression of miR-10b correlated to poorer outcomes in Stages IIII of gastric cancer, confirming its oncogenic role26. In the work by Liu et al., (2012),
authors established that miR-10b promoted tumorigenesis via the RhoC/AKT
pathway, through the inhibition of the target tumor suppressor gene HOXD1027. To
provide an alternate perspective where miR-10b was found to act as a tumor
suppressor, in a study by Li et al. (2014), the authors found that DNA methylation
yielded miR-10b acting as a tumor suppressor in gastric cancer. Using a series of in
vitro experiments, it was established that overexpression of miR-10b led to decreased
tumor progression and invasion, as mediated by the correlated CpG islands and via
specific targeting of the gene T-cell lymphoma invasion and metastasis (Tiam1)28.
This case provides more evidence of the diverse role of miR-10b in gastric cancer,
though its role in an oncogenic context has been more commonly reported and has
been supported by several other studies.
Pancreatic cancer has long been known to be a tumor type that is typically
diagnosed at a late stage and is resistant to most common therapeutic modalities. As
such, not as much is yet known about its early development. In a study by Nakata et
al., (2011), the authors established miR-10b as implicated in the mechanism of
invasion and correlation to a poorer outcome in patients with pancreatic cancer29. Cell
lines and patient samples were used to qualify this effect, with miR-10b found to have
higher expression in the malignant pancreatic cells versus the normal cancer cells,
and yielding a higher degree of cellular invasion, as evaluated via formalin-fixed
paraffin-embedded (FFPE) tissue samples. In another study by Ouyang et al., (2017),

9

the proposed mechanism of action of miR-10b was found to be via the suppression
of TIP30 expression, yielding the promotion of EGF and TGF-b activity on the
mechanisms of migration and invasion17. In the work by Preis et al., (2011), authors
characterized a panel of miRNAs using in situ hybridization in resected pancreatic
ductal adenocarcinoma (PDAC) to determine whether this panel could be used as a
marker for diagnosis and prognosis, and concluded that miR-10b was the miRNA
found to be the most frequently overexpressed, as compared with tissue from benign
samples. The authors further stratified their sample size according to the therapeutic
regimen received, and were able to identify subsets of patients that yielded more
positive outcome to treatment than those not. The higher the levels of miR-10b that
were found, the higher likelihood of disease progression and poorer overall
outcome30. This leads credence to the established knowledge that miR-10b has been
found to be a therapeutic biomarker in this cancer type and can be used for patient
stratification for optimal treatment efficacy.
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Assessment and treatment of brain malignancies in cancer
As the primary focus of this study is brain tumors and the therapeutic compound
in this study is being modeled in cerebral organoids, this section will focus on the
tumor microenvironment of the brain. When it comes to cancers of the central nervous
system, one of the primary limitations to effective diagnosis and treatment is
accessibility to the tumor. The brain and spinal cord are two of the most protected,
yet vulnerable and critical organs of the human body. Any acute or lasting trauma
carries the risk of severe, long-term effects. When it comes to cancers of the brain
specifically, the gold standard for diagnosis of malignancy is histopathological
confirmation. While this is a relatively confirmatory method to determine the degree
of disease, it presents multiple difficulties due to the extensive nature of the invasive
brain surgery needed to obtain a sample biopsy. Primarily, depending on where in
the brain the lesion is located, it could be difficult to impossible to resect the tumor or
obtain a biopsy without adverse effects. In addition, the average age of many Grade
4 brain tumors is in the 50s-60s, which is an older population that carries a higher
likelihood of co-morbidities, making it less likely that biopsies and more aggressive
treatment routes will be pursued31. Even when there is ability to obtain a biopsy
sample, brain tumors are typically composed of multiple molecular subgroups. In
Grade 4 anaplastic astrocytoma, otherwise known as glioblastoma multiforme, there
have been at least three molecular subgroups that have been characterized
transcriptionally and immunologically; these are the classical, proneural, and
mesenchymal groups. All three subgroups have been found to express varying
mutations, along with evidence for differentially response to existing therapeutic
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modalities, which complicates the ability to determine an effective course of treatment
when a tumor may compose more than one of these subgroups32,

33

. Therefore,

access to a biopsy may be misleading due sampling error or due to the
heterogeneous nature of the biopsy sample. Furthermore, the microenvironment of
the brain has long been known to be unique due to the presence of the blood-brain
barrier (BBB). The BBB is a highly selective, semi-permeable membrane composed
of a network of blood vessels and endothelial cells that tightly regulate the entry and
exit of molecules and cells and work to maintain overall brain homeostasis. This
barrier works in conjunction with immune, glial and neural cells to ensure that the
brain is protected from the external world, via inflammation, pathogens, toxins, injury
and disease34, 35. The BBB is often the rate limiting factor for drug development and
discovery efforts to treat pathologies in the central nervous system. This is due to its
propensity to hinder the majority of existing therapeutics from reaching the
microenvironment of the brain, adding a level of complexity to the administration of
many chemotherapies, targeted agents and immunotherapies35, 36. Advanced forms
of primary brain tumors, along with brain metastases, have been reported to
significantly compromise the blood-brain barrier37. This effect is demonstrated by the
diffusion of gadolinium-based contrast agents in magnetic resonance imaging (MRI),
which delineate the general area and structure of malignant brain tumors and can
indicate whether there is BBB leakage. Under normal circumstances these molecules
are not able to cross the BBB to begin with, and are not supposed to show
enhancement38. This is a double-edged sword, because while this leakage typically
indicates advanced or progressive disease, it means that there is a possibility for
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therapeutics to surpass the compromised blood-brain barrier, and for certain
molecules to directly reach and impact the tumor. Lastly, there is a known a lack of
reliable biomarkers that help monitor the response to tumors in the brain to therapy;
the introduction of a methodology that could detect biomarker modulation in the
bloodstream via miRNA levels would add immeasurable insight due to the ease of
access and ability for longitudinal assessment39. The development of non-invasive
detection methods of cancer would supplement the existing therapeutic toolbox.
One such method that could potentially be applicable to the use of RNA
therapeutics is imaging. Imaging in cancer is a powerful tool used to visualize
morphological as well as functional information such as angiogenesis, mutation
status, cellular invasion, and the presence of specific tumor metabolites. Identifying
and characterizing these imaging biomarkers is key to better understanding tumor
composition, subgroup classification and the building of robust predictive models that
can confer therapeutic benefit. While magnetic resonance imaging (MRI) is the
standard tool used to assess disease status, it has yet to lead to a reliable method to
distinguish between treatment response and progression of cancer in the context of
therapeutic regimens such as radiotherapy and immunotherapy. Imaging features
thought to be associated with progressive disease, as characterized by variations in
contrast enhancement in MRI, may be conflated with pseudo-progression - a
subacute treatment-related effect with features that mirror those of tumor
progression. Another treatment effect is radiation necrosis, a late effect resulting from
stereotactic radiosurgery at the tumor site and surrounding regions. This emphasizes
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the need for enhanced techniques to discriminate between these outcomes in order
to better tailor treatments to patients.
In my past work, several forms of imaging studies were conducted to develop noninvasive

methodologies

to

evaluate

treatment

response

as

a

result

of

immunotherapeutic agents. In the first study, the aim was to evaluate the impact of
anti-PD-1 and anti-CTLA-4 immunotherapy, both separately and together, on
treatment response of brain metastases using standard-of-care MRI scans in a
retrospective clinical study. Identification of an imaging signature that differentiates
between responders and non-responders to immunotherapy in a model of brain
metastasis would allow for better stratification of patients in clinical trials, and to
increase the likelihood of patients receiving more accurate and effective treatments
and not treatments that maybe confer toxicity with no benefit. The second aim of this
work was to identify imaging biomarkers that could be predictive of response in brain
metastatic disease to these two forms of immunotherapy. Metastases in the brain are
unique in that they involve a high degree of immune response activation, given that
the blood-brain barrier (BBB) is often significantly compromised due to the nature of
the tumor, and they become immunologically “hot” tumors, as compared to primary
brain tumors, which are “cold” tumors, due to the relative lack of immune cell
involvement. Treatment-related effects such as pseudo-progression and radiation
necrosis have also been found to activate the immune system, and are theorized to
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yield differential signals via imaging.
An example of an axial T1 imaging
sequence is shown (Figure 3).
Metastatic lesions to the brain are
also often unique due to their degree
of infiltration and fluidity. Contrast
enhancement, shown in yellow, is an
indicator

of

active,

proliferating

tumor best reflected on T1-post
weighted

images;

edema

is

a

marker of fluid content in the tumor
lesion and is associated with high
levels

of

aggressiveness

and

invasion. This signal is typically

Figure 3. Segmentation of imaging phenotypes.
Axial T1 MRI scan of a metastatic lesion to the
brain annotated with imaging phenotypes, labeled
below: Yellow: active tumor enhancement; Light
Red: necrosis; Purple: hemorrhage; Blue: edema;
Red: contralateral white matter

found on T2 FLAIR sequences (blue); and necrosis is a signal that is indicative of
hypoxia and dead tissue, or necrosis, found on T1 images (light red).
Hemorrhage/blood products (purple) are a common finding in certain tumors such as
melanoma brain metastases, as these tumors are characterized with more
vascularization and blood throughout the tumor, as well as having melanin content.
These unique factors are found to be associated with poorer long-term outcomes as
compared to other cancer types and can be captured via imaging with both T1 and
T1 post scans40. Tumor-infiltrating edge was segmented within the enhancement
region on T1 post-contrast weighted images and incorporates an immunologically
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active region around the border of the lesion, a region called the “ring of fire”, where
immune cells begin to infiltrate into the tumor. Contralateral white matter, shown in
dark red, was segmented as normalization for calculation purposes.
Nearly 500 scans of patients who underwent anti-PD-1 and anti-CTLA-4 therapy
at MD Anderson Cancer Center were retrospectively reviewed for this study, with
standard-of-care magnetic resonance images semi-automatically segmented and
electronic medical records evaluated for clinical and demographic information. In
addition, imaging characteristics such as volume and morphology of any tumors and
metastatic lesions were collected using the 3D Slicer image analysis software
(www.slicer.org)41 to investigate potential relationships between these factors with
the eventual goal to build predictive models for the clinic. While the analyses of this
specific work have been on hold, the approach and methodology through which this
study was pursued was extensively tested and can easily be applied to similar studies
that incorporate imaging.
In the second study, the aims were to evaluate the association between CAR Tcell related neurotoxicities and clinical features in a cohort of patients in a clinical trial
at MD Anderson Cancer Center, along with evaluating the association between the
occurrence of these neurotoxicities and the survival of patients. Chimeric antigen
receptor (CAR) T-cell therapy has been found to be a promising intervention for
various malignancies, but is associated with severe toxicities throughout the body.
With reference to the brain, CAR T-cell-related encephalopathy (CRES) involves
confusion, delirium, brain swelling and seizures that can be fatal and impacts a large
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range of patients that undergo CAR T-cell therapy, with the majority sustaining a
Grade 3 or above42-44.
Using the FSL 6.0: FMRIB Software Library45-47, an established neuroimaging tool
for analysis of MRI brain imaging data, all major components of implicated
neuroanatomical sites of neurotoxicity were able to be identified and reconstructed
using standard-of-care baseline MRI scans. The areas of focus were mainly the
volume and distribution of gray and white matter, and the volumes of subcortical
structures in the limbic system, the region theorized to be impacted the most after
this form of therapy. This semi-automatic segmentation of various structures is shown
in Figure 4.
The innovation of this work comes in the form of imaging and clinical data
collection before the administration of the CAR-T cell therapy, where there is a
baseline assessment of the brain microenvironment taken before any evidence of
CRES neurotoxicity occurs. In this way, it can be assessed whether there are
“imaging biomarkers” that can be detected, and later compared to the scan after the
CAR-T cell therapy is administered, in order to evaluate any treatment effects and aid
in the determination of whether there is any correlation or pathology that can be used
to predict or investigate further.
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Figure 4. Imaging phenotypes for evaluation of neurotoxicity. Axial T1 MRI scans
displaying the segmentation of gray matter (yellow), white matter (orange), and
cerebrospinal fluid (green). Shown on the panel on the right are the segmentation of
left and right subcortical regions implicated in the limbic system, which is thought to
contribute to CRES, or neurotoxicity after CAR T-cell therapy

While both of these studies have remained on hold, they have yielded significant
insight into methodologies to non-invasively and qualitatively assess malignancies
and treatment response in the brain. This experience has since been introduced in
the world of miRNA research in the laboratory, where the imaging techniques applied
to scans from the brain have been used in a preliminary study on targeting an
oncogenic miRNA called miR-155, which has been associated with metastatic lesions
in the lungs. This methodology was used to reconstruct these tumors using thoracic
CT scans in a translational therapeutic model and the morphology of tumors was
evaluated (Figure 5).
With the rise in RNA therapeutics, including with the novel compound proposed
in this study, this provides an interesting avenue for further study, wherein non-
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invasive detection of tumor progression, coupled with targeted therapeutics, can lead
to the development of improved and more specific approaches.

A

B

Figure 5. 3D reconstruction of lung metastases. A. Axial CT scan of the thoracic cavity at the
region of the lung. The area has many small lesions and areas of enhancement, indicating
the presence of lesions. The largest one is outlined in the 3D reconstruction of the lungs on
the right panel. B. Workflow for the preliminary study
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As previously mentioned, several limitations currently exist in the study of
cancer, particularly in the translation of biological findings from bench to bedside.
While cancer cell lines, PDX models and in vivo studies continue to provide valuable
mechanistic insight into the progression of cancer, these models have an inherent
difficulty in mimicking the microenvironment in which tumors are initiated and
proliferate in humans, and thus have multiple limitations in their ultimate translation
and generalizability of novel drugs that are designed and developed38, 48.
This study is the first known of its kind to investigate small molecule inhibitors
of miRNAs in cerebral organoids. By definition, organoids are 3D cultures of humanderived cells that are able to develop into tissues that are structurally and
phenotypically similar to the organ of interest. Importantly, they are able to represent
cellular heterogeneity of an organ and can be used to model a number of disease
conditions, along with their treatment responses. When cultivated and stably grown,
they can be used in cancer research to bridge the gaps between in vitro and in vivo
studies and clinical trials in humans and more authentically represent the tissue
microenvironment in which tumors are growing and proliferating49-52.
There are several methodologies that have been described in the generation
of organoids in multiple cancer types. In the work by Krieger et. al (2020), authors
described a brain tumor organoid model, validating that glioblastoma cells invade into
the cerebral organoids via similar mechanisms as they do in vivo, and using singlecell RNA sequencing techniques, were able to distinguish consistent transcriptional
changes across varying patient samples53. In the work by Linkous et al., (2019), a
cerebral organoid glioma model was developed, derived from human embryonic stem
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cells and co-cultured with glioma stem cells. This work established a robust model
where the tumors developed were phenotypically similar to those found to develop in
humans, and allowed for a technique that could model growth and also be used for
drug screening54. The benefit of using similar models is the ability to conduct drug
screening in a more cost-effective, experimentally controlled setting, where organoids
are a closer representation of human tissue response than those found in in vitro or
in vivo contexts. As they are patient-derived, organoids can serve to design and
develop treatments in a personalized medicine approach49. This work incorporates
the use of cerebral organoids derived from human-induced pluripotent stem cells
(iPSCs), which have been an established model in recent years49, 52, 55. The cerebral
organoid model used in this study was initially developed by Dr. Sanjay K. Singh in
the Department of Neurosurgery at MD Anderson Cancer Center, wherein adult
fibroblasts are isolated, grown and expanded. Using specialized neural growth media,
along with additional nutrients specific to brain development, the mechanism of neural
differentiation is induced, with the development of ectoderm and epithelial cells.
When stably grown, these organoids become anatomically representative 3D cultures
with all major brain cell types expressed, namely the multiple forms of neuronal and
glial cells. This provides a powerful and applicable model through which invasion of
brain cancer cells into tissue can be demonstrated and the potency of the novel small
molecule inhibitor can be tested.
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Rationale for the study
In the lab’s previous work56, a robust methodology was established to screen
a primary library of small molecule compounds, with the goal to increase the
generalizability of already FDA-approved and clinically tested agents and expedite
the process of drug development and discovery. This library was screened against a
panel of miRNAs that were determined via comprehensive literature search to be
oncogenic. The previous study identified the small molecule linifanib (ABT-869), a
multi-tyrosine kinase inhibitor targeting VEGF and PDGF to have anti-tumor and antiproliferative effects57-59, as an inhibitor of miR-10b expression in several cancer types.
Previously, linifanib was advanced to the clinic for clinical trials, as it was found to be
effective in anti-tumor effects; however, it failed to meet survival endpoints when
tested against its competing inhibitor sorafenib in advanced hepatocellular
carcinoma60. However, in the screening that was published by the laboratory, this
particular compound was found to potently inhibit this oncogenic miRNA as compared
to other miRNAs.
Small molecule therapeutics provide a unique approach and opportunity for
treatment, as they are generally of a molecular weight conducive to permeate through
membranes, such as the blood brain barrier under normal conditions, and with a
compromised barrier in the cases of malignancy, are more likely to be able to target
and impact the tumor directly. In addition, they possess more optimal characteristics
of solubility and permeability to be able to pervade through membranes and tissues
that may have previously have been impermeable or challenging to diffuse through.
Chemical derivations of small molecule compounds that have been FDA-approved
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and have gone through all of the experimentation and validation of the bench-tobedside pipeline allows for easier application of these agents to novel contexts, in
this case in the targeting of overexpressed and oncogenic miRNAs. This allows for
the generation of new hypotheses and derivations of compounds that have a high
potential of specificity and efficacy and ultimately success in human application.
The goal of this work is to characterize a novel small molecule inhibitor
derivative of linifanib, designed to increase the selectivity and specificity of the small
molecule compound to the nucleotide sequence of oncomiR-10b. Via medicinal
chemistry, structural biology and cancer therapeutics approaches, this novel
compound, IACS-13743, was identified from a number of chemically derived
compounds, with primary objectives to prove direct binding to miR-10b and validate
anti-tumor effects in a screening of multiple malignant cancer types, namely brain
cancer, gastric cancer, pancreatic cancer both in an in vitro and cerebral organoid
context.
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Hypothesis and Aims
The hypothesis of this work is that IACS-13743 can directly bind to oncogenic miR10b, inhibiting molecular pathways that promote tumor progression and malignancy.
To address this hypothesis, the following aims were pursued:
Aim 1: To conduct mechanistic in vitro studies and validate direct binding of IACS13743 to the miR-10b transcript
Aim 2: To validate findings in cerebral organoid studies
Aim 3: To identify oncogenic pathways implicated in the effects of IACS-13743
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Chapter 2. Methods
Compound generation: Approximately 42 small molecule compounds derived from
linifanib (ABT-869) were synthetized by the Institute of Applied Cancer Science
(IACS) at the MD Anderson Cancer Center. After in vitro screening in multiple cell
lines of interest, IACS-13743 was determined to be the primary compound of interest
in this study to be further analyzed.
Microsomal stability assay: This assay, along synthesis and solubility analyses, were
conducted in collaboration with the Institute of Applied Cancer Science (IACS), with
the methodology described by Dr. Barbara Czako. The assay was conducted on a
Beckmann Biomek FXp automation system. The liver microsomal incubation mixture
was composed of liver microsomes (with a concentration of 0.5 mg microsomal
protein/ml), the test compound (1 µM), MgCl2 (3 mM), EDTA (1 mM) in potassium
phosphate buffer (100 mM, pH 7.4). The control substrates used for the assay were
Midazolam and Ketanserin. The reaction was initiated with the addition of an NADPH
regeneration solution (1.3 mM NADPH) and maintained at 37 °C with shaking. At five
sequential time points ranging from 0 to 45 minutes, aliquots of the mixture (50 µL)
were removed and quenched with acetonitrile (100 µL) containing an internal
standard control (imipramine). After vortexing and centrifugation, samples were
analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). The in vitro
T1/2 was then calculated and clearance followed literature61.
Synthesis of inhibitors: The inhibitors provided in this study were developed via
standard chemical transformations. All reagents and materials were obtained from
suppliers such as Sigma-Aldrich, Alfa Aesar, TCI, or Acros. Anhydrous solvents (e.g.,
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THF, DMF, DMA, DMSO, MeOH, DCM, toluene) were purchased from Sigma-Aldrich
and directly used as manufactured without further purifications. Other inhibitors were
purified by preparative high-performance liquid chromatography (HPLC). The identity
and purity of all compounds with reported biological activity was confirmed by NMR
spectroscopy, low-resolution mass spectrometry and HPLC. NMR spectra were
recorded on Bruker instruments operating at 300, 500, or 600 MHz. NMR spectra
were obtained as CDCl3, CD3OD, D2O, (CD3)2SO, (CD3)2CO, C6D6, or CD3CN
solutions (reported in ppm), using tetramethylsilane (0.00 ppm) or residual solvent
(CDCl3, 7.26 ppm; CD3OD, 3.31 ppm; D2O, 4.79 ppm; CD3)2SO, 2.50 ppm;
(CD3)2CO, 2.05 ppm; C6D6, 7.16 ppm; CD3CN, 1.94 ppm) as the reference standard.
Low-resolution mass spectra were collected on either a Waters H class UPLC with a
Waters Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection
between 200 and 400 nm, evaporating light scattering detection, and a SQ detector
mass spectrometer with ESI ionization or a Water I class UPLC with a Waters Acquity
UPLC CSH C18 1.7 μm, 2.1 mm × 50 mm column, UV detection at 254 and 290 nm,
evaporating light scattering detection, and a SQ detector 2 mass spectrometer with
ESI ionization.
Solubility assay: Solubility of the IACS-13743 compound and linifanib were assessed
using the FeSSIF method, which stands for “fasted state simulated intestinal fluid”, to
simulate the microenvironment through which these compounds could dissolve. The
compounds were measured at two different pH levels, normal: 7.4, and slightly acidic:
5.8. The metrics for determination of solubility were classified as 0-10µM as low to no
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solubility, 10µM-80µM as moderate solubility, and values of 80µM and above as
compounds with high solubility.
Detection of compound binding to miRNA: This experiment was conducted in
collaboration with the University of Washington and methodology described by Dr.
Matthew Shortridge. The human pre-miR-10b RNA hairpin sequence (nucleotides 4075, per miRbase) was transcribed enzymatically (T7) and purified using methods
previously described62-67. Ligand detected NMR experiments were conducted on a
Bruker Avance III 600 MHz spectrometer equipped with TCI cryoprobe. The NMR
screening buffer consisted of 20 mM d19-Bis-Tris at pH 6.5, 10 mM sodium chloride,
0.2% tween-20, and 11.1 μM DSA as chemical shift reference (integrates to 100
μM)65,

68

, prepared in 99.99% D2O or 95%H2O/5%D2O. Each ligand was first

dissolved in DMSO to a 10 mM stock concentration. Free ligand screening samples
were prepared at a final DMSO concentration of 10% at a concentration of 100 μM in
NMR screening buffer. This concentration was used as the safe upper limit beyond
which the structure of the RNA would be affected. For RNA target detected
experiments, the lyophilized RNA pellets were dissolved in DMSO-free NMR
screening buffer and heated for 4 min at 90 °C, then snap-cooled for 5 min at −20°C.
1D-1H experiments for both ligand and RNA were collected using the Bruker “zgesgp”
excitation sculpting pulse sequence to suppress background water signal. Data was
collected with 64 scans and 16K data points. Data was processed using 16K zero
points, then Fourier transformed followed by manual phase and baseline correction.
2D-1H TOCSY experiments were collected using the Bruker “mlevesgpph” pulse
sequence with excitation sculpting water suppression, data collected with 32 scans,
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2K × 512 data points, a recycle delay of 1.2 s, and spin-lock mixing time of 80 ms. A
reference, ligand free RNA ([pre-miR-10b] =50µM) TOCSY spectrum was collected
prior to adding 4x of IACS-13743 ([IACS-13743] = 200µM). Concentrations were
lower than typically used in order to help prevent aggregation and precipitation of the
small molecule. All data was processed using NMRPipe and visualized using
SPARKY. Peak assignments and secondary structure mapping were completed
using methods described previously65-67.

In vitro experiments: Cell line selection and maintenance: Using the Cancer Cell
Line Encyclopedia (CCLE)69, in-house cancer cell lines were screened to identify
cancer and tissue types with significant levels of miR-10b expression level (Figure 6).
Initial screening experiments were conducted using the MCF7 and MDA-MB-231
cancer cell lines, but as experimentation was conducted with various other cancer
cell types, this was shifted to more representative cell lines for the second phase of
this experiment, due to better characterization and compound treatment response in
these cancer types. For the purposes of in vitro experiments, cell lines were selected
with varying high expression levels of this microRNA, and were also validated to be
highly overexpressed, as substantiated by additional clinical and survival data in The
Cancer Genome Atlas (TCGA).
All experiments were performed using the human-derived cell lines U251 and
LN229 (brain cancer), AGS and SNU-1 (gastric cancer), and AsPC-1 and PANC-1
(pancreatic cancer). The two cell lines chosen for brain cancer analysis accounted
for PTEN mutation status; PTEN is a tumor suppressor gene found to have the most
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frequent mutation (35-40%) in glioblastoma and its dysregulation is found to
potentially lead to differential treatment response32, 70; U251 has a two base pair
duplication at PTEN, yielding a frameshift mutation, whereas the LN229 cell line is

hsa-miR-10b nanostring (log2)

wildtype for this gene.
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Figure 6. Expression level miR-10b in cancer cell lines according to tissue type.

Cell lines were obtained from the American Type Culture Collection and grown
and maintained per instructions from the supplier. U251 and PANC-1 cell lines were
cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and LN229 was
cultured in DMEM with 5% FBS. AGS was cultured in F12K medium supplemented
with 10% FBS. Both SNU-1 and AsPC-1 cell lines were cultured in RPMI, with 10%
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FBS added. All cells were kept at 37oC in a humidified atmosphere of 5% CO2, and
underwent regular mycoplasma testing. All in vitro experiments were conducted when
cells were 70-80% confluent.
Dose-response curves: IC50 dose-response curves were determined using the MTS
assay system. 5,000 cells of each cell line were plated in 96-well microculture plates
in replicates of 6. When cells became adherent, 10 sequentially decreasing doses of
IACS-13743 were diluted into new media and added to 10 wells. Control wells were
included for comparison. After 48 hours, MTS reagent was added to each well at the
same time of day as treatment and incubated for 2 hours at 37oC. The optical density
(OD) was read at 490nm on a microplate spectrophotometer and data analyzed to
determine the IC50 via the dose-response curve method in GraphPad Prism.
Proliferation assay: The impact of the compound on cellular proliferation was
assessed, with 5,000 cells in each cell line seeded in replicates of 6 in a 96 well plate
and treated with DMSO or IACS-13743. After 48 hours, cells were treated with the
MTS reagent and optical density read, in a method similar to the dose-response
curves. Data was analyzed via GraphPad Prism.
Quantitative real time PCR analysis: RNA was isolated utilizing Trizol (Invitrogen) and
the Direct-zol RNA Miniprep kit (Zymo Research). RNA concentration was assessed
with the NanoDrop ND-1000 spectrophotometer (ThermoFisher Scientific). miR-10b
expression was tested using qRT-PCR. Cells were seeded in 6 well plates 24 hours
before treatment, at a cell confluency of 50-60%. Each cell line was treated with 10µM
of compound or the control compound dimethyl sulfoxide (DMSO), the solvent for the
compound. RNA was collected after the 48-hour time point. Expression of miR-10b
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was assessed utilizing the TaqMan microRNA assay (Applied Biosystems). The
complementary DNA (cDNA) was synthesized using the TaqMan Reverse
Transcription Reagents kit (Applied Biosystems) and was used with the TaqMan
probes and Supermix (BioRad) for qRT-PCR analysis. The primers of interest were
hsa-miR-10b and the normalizers U6 or U48, used as internal controls. All
experiments were performed in triplicate, with all samples normalized to the internal
controls and relative expression levels calculated using the 2- DDCt method.
Clonogenic assay: In vitro clonogenic assays were conducted with adherent lines
seeded in 12-well plates, treated for two weeks, and stained with crystal violet.
Images were analyzed via the software ImageJ where colonies were semiautomatically counted and compared across groups.
Flow cytometry: Apoptosis and cell cycle assay: In 6-well plates, 1 x 105 cells/mL
were added into each well. After 24 hours, sequential concentrations of DMSO and
IACS-13743 were administered and the plates were incubated for 48 hours. The
supernatant and adherent cells were collected and centrifugated. Each dose was
done in triplicate, with each sample composing two wells. For apoptosis analysis, the
supernatant was discarded after centrifugation and the pellet washed with PBS twice.
Then, BD Annexin V-FITC/PI was used to stain the cells for analysis via flow
cytometry on a Gallios machine. For cell cycle analysis, after washing with PBS, cells
were fixed with ethanol and incubated. They were then treated with RNase enzyme
and counts analyzed across groups.
Cell sorting: For co-culturing with cerebral organoids, the brain cancer cell lines U251
and LN229 were transduced with an RFP lentiviral vector expressing MCherry and
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luciferase, and sorted twice via an Aria Influx Cell Sorter. Cell lines were expanded
to at least 1 x 106 cells/mL and properly grown, maintained and stored until
experiments began.
Western blot analysis: Western blot analysis was conducted according to standard
established protocols, as outlined in the laboratory’s previous work56. Briefly, proteins
were extracted and collected from lysed cells from all screened cell lines of interest.
The Bradford assay was used to measure and normalize protein concentrations.
Quantification of protein expression after the experiment was conducted using the
image analysis software ImageJ71.
Cerebral organoids: Human induced pluripotent stem cell (iPSC) derived cerebral
organoids were obtained, courtesy of Dr. Sanjay Singh and Dr. Frederick Lang in the
Department of Neurosurgery at MD Anderson Cancer Center. Organoids were
maintained in a specialized neural based media on a continuous running shaker
inside a 37oC incubator. After maturation, organoids were moved to 24-well ultra-low
attachment plates, and individually co-cultured with 5 x 105 – 1 x 106 cells from RFP
cell sorted brain cancer cell lines until RFP signal on individual cells was clear on the
surface of the organoid, approximately 48-72 hours, indicating cell adherence and
attachment. Organoids were then moved to 6 well plates and grouped into triplicates
within each of the wells. The treatment regimen of control, and the group treated with
the compound IACS-13743 was started, at an analogous schedule to in vitro
experiments. For fixation and embedding for in situ hybridization, the organoids were
processed using 4% PFA and placed in optimal cutting temperature (OCT) compound
in -80oC for sectioning.
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Reverse Phase Protein Array (RPPA): Proteomics analysis was conducted at the
Reverse Phase Protein Array Core facility at MD Anderson Cancer Center, the
methods of which are described in detail in the referenced publication72. Briefly,
controls and treated samples were analyzed in triplicate for 486 unique antibodies.
The outputs were then normalized for protein loading and transformed to the linear
value, and the normalized data was log2 transformed (log2(x+1)) and sorted by FDRadjusted p-values with a significance level of p < 0.05. Differentially expressed
proteins between the groups were identified using the moderated t-test from the
LIMMA package73. The results of the differential expression analysis (fold changes
and p-values) were displayed in a volcano plot, highlighting proteins of interest.
Analyses and graphical representations were carried out in R (http:///www.rproject.org/). The clusterProfiler package was used for data visualization and
analysis.74 Differentially expressed genes were log2 normalized. For pathway
analysis, the Hallmark gene set75 and Gene Ontology76, 77 datasets were used.
Statistical analysis: All statistical analyses were performed in GraphPad Prism
Version 8 or 9. All tests were two-sided and considered statistically significant at the
p < 0.05 level. Graphs with error bars represent mean ± SEM.
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Chapter 3. Results

Aim 1: To conduct mechanistic in vitro studies and validate direct binding of IACS13743 to the miR-10b transcript

Screening of compounds in the secondary library: In the past work, a library of
small molecules was screened for miRNA specificity and linifanib (ABT-869) was
identified as a viable drug candidate to specifically target a dysregulated microRNA
in cancer - microRNA-10b56. While this effect was shown in an in vitro context, due
to the insolubility of the parent molecule, direct molecular binding between the
sequence of miR-10b and linifanib was not able to be confirmed. The generation of a
secondary small molecule library allowed for the ability to evaluate molecules that
were modified and found to yield greater levels of solubility and specificity to the
sequence of this miRNA. In this aim, a panel of cell lines derived from multiple cancer
types with significant levels of miR-10b was used to validate the function of this
molecule in vitro, to provide a broader perspective as to its mechanistic function.

IACS-13743 is an inhibitor of oncogenic miR-10b: To identify a novel small
molecule compound candidate, 42 small molecules were developed via structurebased design from the parent compound linifanib, and after a rigorous screening
process, IACS-13743 was identified as the candidate for further in vitro studies
(Figure 7). Based on the structure of linifanib, a 2-dimensional structure-activity
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relationship (SAR) study was performed by making structural modifications in the 1Hindazol-3-amine and the 2-fluoro-5-methylphenyl region of the molecule.

Figure 7. Structure-activity relationship (SAR) studies of microRNA-10b inhibitors
based on the structure of linifanib. The development of derivative compounds initially
yielded 42 compounds and was further filtered to 8 compounds via luciferase assay.
Compounds 25 emerged as the candidate for further in vitro analyses
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As an early study identified miR-10b identified as an oncogenic marker in
breast cancer78, 79, the screening of the secondary library derived from linifanib was
conducted in the MCF-7 cell line using a luciferase assay, using DMSO as the
negative control and the parent compound linifanib as the positive control. Briefly, the
luciferase assay is a rapid screening methodology utilized to detect miRNA
expression levels. When a molecule or inhibitor targets the miRNA of interest, the
mature sequence of the microRNA is decreased due to the inability to be processed
from the premature form, and the luciferase gene is expressed. If the compound is
not found to be specific to the sequence of miRNA and by extension doesn’t bind or
impact the activity in any way, the miRNA binds to the target sequence and inhibits
the expression of the luciferase gene, decreasing its effect. As shown in Figure 8,
based on activity in the primary cell assay, 8 compounds yielded a fold change
greater > 2 in the MCF-7 cell line and were prioritized for further screening in the
MDA-MB-231 cell line. Compounds 11 and 25 were two of the top hits from both
screenings, and were utilized for further in vitro assays in the selected panel of cancer
cell lines.
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Figure 8. Luciferase screening of secondary candidate compounds in the first part of
this study. This experiment narrowed down compounds from secondary library
generation to Compound 11 and Compound 25 and later focused on Compound 25
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These SAR studies revealed that the 1H-indazol-3-amine moiety is not
required for activity, and can be replaced by a variety of heterocycles as depicted on
Figure 8. Small variations in the substituent pattern on the phenyl ring were also
tolerated, as shown by IACS-13724.

As a result of this study, IACS-13743

(Compound 25) emerged as a leading compound. IACS-13743, or Compound 25,
has acceptable calculated properties and is Rule-of-Five80 compliant, with a cLogP of
4.75, TPSA of 69, 3 H-bond donors of 2 H-bond acceptors. The compound has low
kinetic solubility of 0.71 µM in PBS (pH 7.4) but excellent solubility in buffer that
simulates fed state (FeSSIF) (pH 5.8) with a solubility of 51 µM. The compound was
also found to exhibit favorable microsomal liver stability in human, rat and mouse
microsomes with a clearance level of 14.9 mL/min/kg, 41 mL/min/kg and 58
mL/min/kg, respectively, and a half-life of 116 min, 60 min and 92 min, respectively
(Table 1). Clearance level (CLint) is a measure of the amount of drug being cleared
from the liver or hepatic system. Therefore, the higher the clearance level, the more
favorable the effect of the drug can be, as it has a longer duration in the system. While
the clearance levels for the derivative compound IACS-13743 fall under the “medium
clearance” classification, their values do not significantly vary from the parent
compound linifanib. Based on the activity of the compound, as well as the calculated
and in vitro pharmaceutical properties, the compound was further evaluated.
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Compound
IACS-13743

Linifanib

Species
MLM
RLM
HLM
MLM
RLM
HLM

Half-life (min)
92.8
60.4
116
63.1
122
197

CLint(mL/min/kg)
58.9
41.1
14.9
86.5
20.4
8.8

Table 1: Microsomal stability assay evaluating the half-life and clearance levels of
IACS-13743 and the parent compound linifanib. Mouse liver microsome (MLM), rat
liver microsome (RLM), human liver microsome (HLM)

In preliminary experiments evaluating the candidate compounds for the
second phase this study, several cancer types were evaluated and considered for
inclusion. Initial studies in hepatocellular carcinoma and triple negative breast cancer
were conducted for Compounds 11 and 25, but yielded data that was not consistent
between the compounds, indicating that the mechanisms of tumor impact in this
context may not have been miR-10b mediated or the tissue tumor type was not
receptive to the compound. Brain cancer, gastric cancer, and pancreatic cancer have
long been studied in the context of miR-10b13, 14, 16, 17, 29 and had supporting data of
its significant expression and impact in these cancers, so they were chosen for further
screenings.
The antitumor efficacy of IACS-13743 was evaluated in the six cell lines of
interest. Half-maximal inhibitory concentration (IC50) was determined for each cell line
at 24 hours and 48 hours post-treatment. The time point at 48 hours was found to be
the time point that yielded the lowest IC50 value for the majority of cell lines, indicating
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the most potent effect81, and was thereby chosen as the time point for further in vitro
experiments (Figure 9, Figure 10).
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Figure 9: IC50 values of each cell line at 24 hours after treatment with IACS-13743
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however this graph shows that tissue type may play an important role in each cancer
cell type sensitivity to the compound.
The two primary brain cancer cell lines (U251 and LN229) were shown to have
comparable IC50 levels and relatively higher miRNA expression level. In fact, from the
data gathered in the Cancer Cell Line Encyclopedia (CCLE), the U251 cell line was
found to have the highest expression of miR-10b of all analyzed brain cancer cell
lines, which is consistent with this data and is the rationale for its primary use in this
study. Both gastric cancer cell lines had IC50 values under 5µM, with AGS being a
primary cancer cell line and SNU-1 a metastatic cell line. For the two pancreatic cell
lines, AsPC-1 is a metastatic pancreatic ductal adenocarcinoma line and showed a
higher IC50 value than PANC-1, a primary PDAC line, indicating a varying level of
efficacy of the drug. While all IC50 values were found to be under 10µM, which is
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promising in terms of its potential mechanism of action in a therapeutic context, this
data indicates that the efficacy of this compound may be further dependent on tissue
type and is a factor kept under consideration while completing the assays (Figure 11).
The MTS proliferation assay was conducted in order to evaluate cellular
proliferation and the impact of the compound, with a regular time point of every 24
hours, over a period of 96 hours. Each cell line was standardized in the cell number
and treated with 5 and 10µM of IACS-13743, which falls both above and below the
ranges of the IC50 values in the screened cell lines. This was done to both to validate
whether the IC50 value that was evaluated was within range and accurately collected,
and also to have a more comprehensive assessment of the timeline through which
there is impact of the compound.
As shown in the subsequent figures, most of the cell lines began indicating
significant impact to proliferation between 24 and 48 hours after administration of the
compound. The 10µM dose of the compound induced a significant decrease in
proliferation in all cell lines beginning at 48 hours of treatment, while a few of the cell
lines began yielding differences at 24 hours (Figure 12). This is consistent with their
dose-response data; for the cell lines with lower IC50 values, their proliferation is
impacted at earlier time points and the cells undergo apoptosis sooner due to the
sensistivity to the compound. In our data, this is shown in two of our cell lines,
indicating that lower doses may be needed to more accurately determine the timeline
of impact. However, the majority of the cell lines saw impact after 48 hours of
treatment administration.
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Coupled with the experimental IC50 data, 48 hours post-treatment was thereby
confirmed as the time point for further in vitro experiments. The results of this
proliferation experiment also confirm that the compound IACS-13743 is indeed
effective against tumor cells from multiple tissue types with higher levels of miR-10b
expression at concentrations that are promising for therapeutic purposes. Moreover,
there is a temporal component that needs to be taken into consideration – it is not an
immediate acting agent, and requires approximately two days to induce tumor cell
death. This effect is also persistent, and the cell counts do not appear to recover
given our data up to 96 hours, with the higher dose.
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Figure 12. Proliferation assay conducted on six cell lines, treated with control, 5µM or
10µM of IACS-13743. Symbols signify the group compared to the DMSO control, with
° representing DMSO vs. 5µM and * representing DMSO vs. 10µM. One symbol
indicates p < 0.05, two indicate p < 0.01, three indicate p < 0.001 and four indicate p
< 0.0001.
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For a more qualitative assessment of the effect of the compound on the two
brain cancer cell lines, the morphology of the cells was evaluated for LN229 and
U251, shown in Figure 13. Equal amounts of cells were plated in 6 well plates and
were allowed to reach 70-80% confluence. At this point, the compound was
administered at 10µM, and images were taken using a standard microscope at both
24 hours and 48 hours after treatment.
Our previous in vitro experiments had indicated that the effect of the compound
became more potent at the 48-hour time point. As shown in the images, at 24 hours
after treatment, the cells appeared unaffected and still remained attached to the well
and relatively confluent. At that time point, there were no visible indications of the
impact from the compound as of yet. By 48 hours after treatment however,
qualitatively many of the cells were floating within the wells, indicating they had
undergone apoptosis, and as shown in the image, much less amounts remained
adherent to the floor of the wells and the morphology had changed to more circular
than tubular, the latter of which is characteristic of these two brain cancer cell lines,
indicating the cells had been impacted.
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Figure 13: Cellular morphology of the brain cancer cell lines at control and 10µM of IACS13743 over 24 and 48 hours. Images taken at 20X magnification.
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The inhibition of miR-10b expression by IACS-13743 was evaluated via
quantitative real-time polymerase chain reaction or qRT-PCR. It is presented as the
fold change normalized to internal control U6 in the U251 brain cancer cell line. It
indicates a significant downregulation of the expression of the miRNA after treatment
with the compound (Figure 14A). To test the compound specificity for miR-10b and
to ensure that it does not specifically target other miRNAs, qRT-PCR was conducted
to test the compound against a miRNA with a very similar nucleotide sequence to
assess whether it also binds and impacts expression level. The miRNA miR-10a is
the other member of the miR-10 family and its sequence differs from miR-10b by only
one nucleotide. In theory, given the sequence similarity, if the IACS-13743 compound
is not very specific, it should also target this miRNA similarly and downregulate its
expression. However, when evaluating both miRNAs with their respective control
groups, it was found that the compound significantly targeted miR-10b expression
level and not miR-10a, solidifying the hypothesis that IACS-13743 specifically targets
oncogenic miR-10b (Figure 14B)
A

A

B

Figure 14. A. qRT-PCR evaluating miR-10b expression in U251 with and without treatment
with IACS-13743. B. qRT-PCR evaluating expression of miR-10a and miR-10b
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A clonogenic assay was conducted to investigate the formation of colonies after
treatment with IACS-13743; data is shown for the U251 brain cancer cell line, the cell
line with the highest expression level of miR-10b in the study. As shown in Figure
15A, there is a clear decrease in the growth and proliferation of the cancer cells in a
dose-dependent manner, beginning at 1µM up to 5µM, where no colonies are
detected, clearly demonstrating the impact of the compound.
Next, the degree of apoptosis was assessed via flow cytometry, using the
Annexin V/PI FITC model. As shown in Figure 15A, it was found that at 5µM, there
was a clear increase of approximately 4.5 times in total apoptotic cells, as compared
to the control group in the U251 brain cancer cell line. In this analysis, total apoptotic
cells are defined as the sum of the early apoptotic and late apoptotic cells. Necrosis,
or accidental cell death, was not accounted for in this value, as apoptosis and
necrosis ultimately indicate different cell death mechanisms82. When evaluated at a
dose level of 10µM, the cell amounts were approximately the same in this cell line,
indicating that the rate of apoptosis plateaus after a certain threshold is met (Figure
15C, left). In order to investigate whether this effect was tissue specific, this analysis
was also conducted in the AGS cell line, which has a lower IC50 value using the
compound of interest than U251 (3.722µM to 7.686µM). It was found that while there
was a significant increase in apoptotic cells at 5µM compared to control, the sharp
increase occurred by 10µM, with nearly 60% of cells found to have undergone
apoptosis (Figure 15C, right). This confirms that this gastric cell line is more sensitive
to the compound, as shown by its IC50 value. It remains to be shown to what degree
this is a tissue specific effect.
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Lastly, cell cycle analysis via flow cytometry was conducted. In the U251 brain
cancer cell line, while other cellular checkpoints remained approximately the same, a
significant increase was shown at the G2/M phase, indicating cell cycle arrest. Cell
cycle arrest at this stage is an indicator of potential induction of apoptosis, which is
found to be consistent with the ongoing in vitro results (Figure 15D).
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Figure 15. Panel of in vitro experiments.
A. Clonogenic assay in the U251 brain cancer cell line indicating significant decrease in colony
formation in a dose-dependent manner.
B. Apoptotic assay done via Annexin V/PI FITC flow cytometry analysis indicating a 4.5x
change in early and late apoptotic cells after treatment with 5µM of IACS-13743
C. Comparison of degree of apoptosis at two doses between U251 brain cancer and AGS
gastric cell line.
D. Cell cycle analysis done via flow cytometry indicating cell cycle arrest at the G2/M phase.
For all figures, * represents p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001 and ****
indicates p < 0.0001.
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IACS-13743 directly binds to the precursor transcript of miR-10b. Ligand and
target detected NMR experiments were used to assess whether IACS-13743 directly
binds the apical loop structure common to both the primary-and precursor miR-10b
transcripts (Figure 16). This apical loop region is critical for key enzymatic processing
steps of the miRNA biogenesis pathway including nuclear processing by Drosha
(primary) and cytoplasmic processing by Dicer cleavage (precursor). Identifying
compounds that bind this apical loop region may provide dual inhibition of both
enzymatic steps, thereby reducing the overexpression of mature miR-10b. To detect
direct binding, the ligand detected 1D-1H line broadening approach was used to
confirm a direct interaction with the RNA (Figure 16)68, 83. In this experiment, the free
ligand is held at a constant 100µM concentration, then slowly titrated with the target
RNA. The height of the ligand chemical shift resonance signals are measured at each
titration point and the decrease in ligand signal upon addition of RNA target is
proportional to the affinity (KD) and size of the RNA target.68, 83 This approach detects
a wide dynamic range of binding affinities between low nM to mid mM KD.68 Nonbinding compounds show no change in chemical shift or peak height; therefore, this
approach can be used in a binary fashion to confirm binding. For IACS-13743, a
large decrease in peak signal was found (Figure 16A) between the free (black) and
bound ligand samples, particularly the methyl protons (starred) which is indicative of
direct binding of the two components.
To confirm the direct binding using ligand detected NMR methods, target
detect NMR methods, which monitor changes of the RNA upon titration of the ligand
using the 2D 1H-1H TOCSY NMR experiment, were also conducted (Figure 16B). In
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this experiment, 50µM of pre-miR-10b sequence was titrated with 100µM of IACS13743. After resonance assignment of the pre-miR-10b apical loop, a binding site for
IACS-13743 was able to be identified. This approach has been used in previous work
to map binding sites of small molecules and macrocyclic ligands.83-85 The pyrimidines
which showed the largest chemical shift in the 2D-1H-1H TOCSY experiment were
identified as follows: (U6, U7, U8, U26, C27, C29 and U33). There were also weaker
shifts noted in the remaining dsRNA stem region, however, no chemical shift change
was seen in the upper loop region (C18, C19, U21, or U23). From these NMR results,
the binding site location of IACS-13743 can be approximated onto the pre-miR-10b
structure (Figure 16C). Here, the chemical shift changes are mapped on to the NMR
derived secondary structure and a 3D model of pre-miR-10b is generated. The 3D
model of pre-miR10b was created using the NMR derived secondary structure and
proton chemical shifts as structure restraints for the FARFAR2 method.86 Identifying
compounds that bind in this region, the junction between the apical loop and apical
stem, may be particularly interesting as this region correlates to the Dicer cleavage
site of pre-miR-10b (5’ Dicer cut site U12, 3’ Dicer cut site C27). These data strongly
support that IACS-13743 directly binds to the hairpin structure of precursor miR-10b.
In addition, this finding allows for more precise approximation of how and where the
molecule is specifically binding, and will provide valuable insight into further
modifications of this molecule if a tertiary compound library is pursued, or for novel
compounds during development for therapeutic purposes.
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Figure 16. Confirmation of direct interaction between IACS-13743 and miR-10b using NMR:
A.) Methyl protons (starred) of IACS-13743 resonate at a chemical shift of 2.23ppm. Ligand
detect, line broadening experiments show significant line broadening upon addition of pre-miR10b. Here, the free ligand was maintained at constant at 100mM (black). To measure a binding
event, 10mM of pre-miR-10b sequence was added to the free ligand sample (red) and data
were collected identically. The decrease in peak signal is indicative of direct binding interaction
B.) To confirm binding and identify the ligand binding site on the RNA, we conducted a target
detect NMR experiment which monitors changes in chemical shift of pyrimidine H5-H6 protons;
2D TOCSY. The free 50uM of pre-miR10b sequence (black) was titrated with 100uM IACS13743 (red). Overlaying the two NMR spectra show which pyrimidine residues are most likely
near the ligand. C.) The pyrimidine peaks that show largest chemical shift change are mapped
onto the NMR derived secondary structure of miR-10b with bases perturbed in the presence of
IACS-13743, colored in red. A model of the pre-miR-10b 3D-structure was generated with
FARFAR2 and the results from B also mapped on to this structure. Given many of the largest
chemical shift changes occur in a localized region near the Dicer cleave site, suggests this
compound could inhibit processing of pre-miR10b.
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The same direct binding experiments were conducted in the parent compound
linifanib for comparison and to identify whether the same effects were seen as those
in IACS-13743. Due to the insolubility of the molecule, however, direct binding of the
target RNA and linifanib were unable to be confirmed. As shown in Figure 17, there
is no decrease in peak signal, as in the one shown in IACS-13743 and there is no
line broadening portrayed in the spectra, indicating that it cannot be concluded either
way that linifanib directly binds miR-10b, as it can be for IACS-13743. (Figure 17).
This is encouraging data, as since linifanib advanced to clinical trials, it possesses
the capability to be therapeutically used in humans. With further testing of IACS13743, and with this data on the direct binding, this increases its potential to be used
in a clinical setting in indications that have miR-10b overexpression.

Figure 17. Direct binding experiment for linifanib via NMR. No line broadening detected
and there was no decrease in peak signal, as found in the derivative compound, indicating
that direct binding could not be confirmed
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IACS-13743 functions via miR-10b and the kinase pathway. To confirm that the
mechanism of IACS-13743 operates via the miR-10b pathway and not via the target
kinases, an in-house kinase assay was conducted to measure the enzymatic activity
of the compound as it compares to the parent compound linifanib. The ADPGlo
Kinase Assay was used for this experiment, which is an established and highly
sensitive biochemical approach87 to kinase screening and profiling of molecular
agonists and antagonists. The kinase of interest for this experiment was PDGFRb,
which is one of the primary targets of the parent compound linifanib, the other being
VEGF. The IC50 value of the novel compound and parent compound was sought as
they relate to this kinase; IC50 in this context is a measure of chemical potency and
differs from the IC50 values derived from cellular in vitro studies, as this is a
biochemical assay comparing the activity of the inhibitors, with no consideration of
cell or cancer type. According to the literature, linifanib has a biochemical IC50 of
approximately 66nM in PDGFRb cell-free kinase assays, which shows a high degree
of efficacy through that kinase pathway88. The expectation for this assay is that IACS13743 would have a greater IC50 than that of linifanib, because it would provide
evidence that the effects that are seen are not through the interaction with the kinases
or going through a kinase pathway, but that it is also operating through the direct
binding and inhibition of the oncogenic miRNA. Therefore, it would have less affinity
to the kinases and would require a larger amount to yield efficacy. The experimental
results generated in the laboratory have supported this effect, as detected by a
luminometer and reported via relative luminescence units (RLU). An IC50 of 251.9nM
for IACS-13743 and 81.74nM for linifanib is reported against the kinase PDGFb.
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As this was a preliminary evaluation of one specific kinase done in-house, it
requires external validation by an established institution with biochemical expertise
and preferably a host of kinases can be evaluated in kind. In a preliminary result from
collaborators at IACS, a panel of kinases that linifanib is known to act through was
evaluated. It was found that while IACS-13743 had low nanomolar activity towards
the same kinases, indicating that there is activity upon these kinases, the values were
all higher than the activity of linifanib. This indicates that it requires more of the small
molecule compound to be active towards these kinases, and since we were able to
detect direct binding towards miR-10b, it provides evidence for a potential dual
mechanism, wherein it is mechanistically operating on both pathways. This could be
beneficial from a therapeutic standpoint, as simply stated, if there is treatment
resistance via one oncogenic mechanism, the compound could work through the
other.
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Aim 2: To validate findings in cerebral organoid studies

Cerebral organoids are a model of brain cancer growth. The brain cancer cell
lines U251 and LN229 were evaluated in a model of cerebral organoids, derived from
human induced pluripotent stem cells (iPSCs). The brain was chosen to be modeled
out of the three cancer types in this study, as within The Cancer Genome Atlas
(TCGA)89 it was shown that the brain had the greatest upregulation of miR-10b in
cancer between normal and glioblastoma multiforme cohorts as compared to the
normal and tumor cohorts found in pancreas and stomach (Figure 18A).
To determine this expression level difference of miR-10b among normal and
tumor tissues of these three different cancer types, a Shapiro-Wilk test was first
employed to determine whether or not the data followed a normal distribution. It
verified that the available data did not follow a normal distribution, thus the nonparametric Mann–Whitney test was applied to assess the relationship between
mRNA expression and tissue type in the data from the TCGA. A point plot along with
color key was used to display fold changes and p-values for the comparisons
performed (Figure 18A). A box-and-whisker plot, with the box representing first (lower
bound) and third (upper bound) quartiles, and the whiskers representing 1.5 times
the interquartile range, was used to visualize the distribution of the miRNA data that
was available for the glioblastoma cohort, as compared to the data available for the
normal brain tissue (Figure 18B). All tests were two-sided and considered statistically
significant at the 0.05 level. As shown, it was found that between brain, pancreas and
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stomach, the expression of miR-10b was clearly significantly upregulated as
compared to normal only in the context of brain cancer (Figure 18A).
As glioblastoma multiforme was the first cancer type for which data was
collected in the The Cancer Genome Atlas (TCGA), the majority of available samples
have been analyzed and encoded via the Agilent microarray technology, as opposed
to the newer miRNAseq techniques that were employed for the stomach and
pancreas tissues and the more innovative manner that the datasets have been
processed through. While the sample sizes are shown to be unbalanced, this effect
provides a trending direction through which the levels of this microRNA can be
assessed in multiple tissue types and can be further investigated in alternate models.
In addition, the brain cancer cell lines have consistent expression of miR-10b within
the panel of cell lines and represent a potential robust model to first test the efficacy
in IACS-3743 in organoids.
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A

B

Figure 18. miR-10b expression in The Cancer Genome Atlas (TCGA). A. Comparison
between normal and tumor cohorts in expression of miR-10b in three cancer types of
interest. B. miR-10b expression in normal vs tumor cohorts in glioblastoma
multiforme.
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Cerebral organoids are an innovative method in cancer research to study the
expression of cancer stem cells and cell lines in conjunction with drug development
and therapeutics approaches with novel compounds (Figure 19). It is becoming more
common in biomedical science to introduce models that are derived from patient cells
to mimic the human tumor microenvironment, and more directly test the effects of
therapeutics and develop more personalized intervention methods. Cerebral
organoids, as previously mentioned, are unique in that they are often developed from
patient-derived cells, and can also serve as a robust model to further study brain
malignancies on the pathway from in vitro and in vivo to the clinic.
In this work, this innovative cerebral model was used to answer three main
questions. The first objective was to determine whether a stable model could be
developed using these iPSC-derived cerebral organoids in culture with brain cancer
cell lines with significant levels of miR-10b expression; previously, only glioma stem
cells have been stably and successfully co-cultured within this particular model. The
second objective was to establish and validate the upregulation of miR-10b that has
been established in the literature in a brain tumor context in this cerebral model. Third,
to determine whether this compound is able to decrease the expression levels of the
oncogenic miRNA in this model.
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Figure 19. Diagram of the process used to generate the iPSC-derived cerebral organoids.

To address these questions sequentially, control organoids with no tumor
involvement that had reached steady state of growth were initially analyzed via qRTPCR, to obtain a baseline level of miR-10b expression. The expectation would be that
the levels of expression are low to undetectable, per the past research that has been
conducted wherein expression of this miRNA is not found to be high in normal, noncancerous brain tissue13,

18-20

. Given that all major cell types are meant to be

represented51, the idea would be that the organoids are modeling what occurs
endogenously in human brain development. Prior to co-culturing, both cancer cell
lines were individually tagged with RFP, in order to fluoresce under the microscope
and to detect where the cells would be end up. After tagging, cell lines were expanded
to increase the number of cells, and then sorted twice via flow cytometry, to ensure
that all cells would be RFP-positive when placed in with the organoids. The organoids
were then co-cultured individually, with either brain cancer cell line LN229 or U251.
Shown in Figure 20A are the co-cultured organoids shown under the fluorescent
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microscope at approximately 48 hours and 2 weeks post co-culture. All tumorigenic
cells were tagged with red fluorescent protein (RFP) and are easily seen at 48 hours,
as at that point they were still on the surface of the organoid and had not yet invaded
into the tissue microenvironment. Over the course of one to two weeks, as migration
and proliferation occurred throughout the tissue, what can be seen is enhanced bright
red areas within and throughout the organoid, but not isolated and circumscribed foci
as before. The signal is more diffuse and the cells appear to have aggregated as they
moved throughout the organoid. This indicates that the cells had migrated inwards
and had begun proliferating, showing that the brain cancer cells were successfully
co-cultured in the organoids. Expression of the miRNA was then measured via qRTPCR and the effect was confirmed as shown by the data showing a significant
increase in miR-10b expression in the co-cultured organoids with LN229 and a
trending increase with U251 (Figure 20B).
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Figure 20: Cerebral organoid studies. A. (left) Cerebral organoid co-cultured with LN229 brain cancer
cell line. (right) Cerebral organoid shown at 2 weeks post-co-culture. B. qRT-PCR confirming
significant upregulation of miR-10b in the LN229 brain cancer co-cultured cerebral organoid model and
a trending upregulation in the U251 brain cancer cell line model. C. miR-10b expression levels in
cerebral organoids after treatment with IACS-13743. Both cell lines showed significant downregulation
of expression.
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Importantly, up until this point, these iPSC-derived cerebral organoids have
only been successfully co-cultured with glioma stem cells (GSCs), which are cells
that possess the capability of differentiation and self-renewal, characteristic of cancer
stem cells and are thought to be more resistant to therapy90. They differ from
traditional cancer cell lines in how they are maintained and grown for these reasons.
In this work, two established brain cancer cell lines were used, which were
conditioned over time with specialized neural-based media and nutrients that are
compatible with the growth of the organoid, and the study was able to prove increased
expression of this oncogenic biomarker.
To further confirm that IACS-13743 yields an impact in this more advanced in
vitro model, the co-cultured organoids were treated with varying doses of the
compound and levels were evaluated using qRT-PCR. Significant downregulation of
miR-10b with 10µM of treatment with the compound after 48 hours was detected in
both brain cancer cell lines (Figure 20C). This supports the in vitro data well wherein
at 5µM there was not a detectable change in expression, whereas after the IC50
amount for LN229 (7.395µM) and for U251 (7.686µM), there was a significant
decrease in the expression of miR-10b. An in-situ hybridization experiment was
conducted to qualitatively confirm the effect of this compound treatment on miR-10b
expression at the two doses in the two cell lines, with U6 serving as the positive
control and scramble miRNA as the negative control. Control in this context
represents cerebral organoids that have no tumor cells, whereas the DMSO group
represents vehicle treatment. Qualitatively, miR-10b is clearly expressed in the tumor
co-cultured organoids as compared to the control organoids.

(Figure 20). This
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confirms that the compound has the potential to work in more models than just
biochemical and in vitro, and can potentially be used downstream in higher order
models.

Control

U251

LN229
DMSO

5μM

10μM

DMSO

5μM

10μM

miR-10b

U6

Scramble

Figure 20. Representative in situ hybridization images of U251 and LN229 cerebral organoid
model with IACS-13743 compound treatment, with U6 serving as positive control and
scramble miRNA as negative control.
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Aim 3: To identify oncogenic pathways implicated in the effects of IACS-13743

Targets of miR-10b and the mechanism of action of IACS-13743.

When

evaluating the impact of oncogenic miRNAs, the traditional approach is looking at the
proposed targets of the overexpressed miRNA. In the initial hypotheses into this
project, datasets of predicted and validated targets of miR-10b were investigated to
determine potential molecular targets to provide potential insight into the mechanism
of action of this microRNA. Using publicly available datasets, namely target prediction
and validation software in conjunction with comprehensive databases such as
Oncomine91 and TCGA89, a series of experimentally validated targets were proposed
using the sequence of miR-10b, by complementarily matching them with the
sequences of potential targets. When a miRNA interacts with mRNA, it binds the
complementary nucleotide sequence, which is called a “canonical” interaction. Noncanonical interactions are when miRNA sequences are similar enough to still bind the
mRNA, but function via other cellular processes and normal mRNA levels and
functionality are not affected.
Using the dataset of experimentally validated targets derived from TargetScan,
which lists sequences collects references of studies that experimentally test the
relationships between microRNAs and genes, and cross-referencing them with
Oncomine, a preliminary list of miR-10b targets were analyzed for the three cancer
types. All available and complete datasets were analyzed, which included six
datasets for malignant brain cancer, three datasets for pancreatic cancer, and two
datasets for gastric cancer. The targets identified were filtered to only those with
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experimental validation in the established miRNA datasets in miRPathDB92, which
was integrated from data with miRTarbase93, TargetScan94 and miRanda95, other
comprehensive miRNA datasets that include target information. Only one gene,
PTEN, was shown to be common across the three cancer types (Figure 21). PTEN
was an experimentally validated target of miR-10b that was shared between these
three cancer types, which indicates a potentially more global mechanism of
oncogenic progression and thus PTEN was proposed as an initial tumor suppressor
gene of interest. This was the first indication of involvement from the PI3K/AKT
pathway.

Pancreas

Stomach
ATF4
ADA
10

142

PTEN
XPA
PDPK1
SFRP1
FNBP1

21
Brain

Figure 21: Venn diagram shown overlap of experimentally derived targets of miR10b-5p from multiple datasets within Oncomine
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Reverse Phase Protein Array (RPPA) analysis was conducted on a subset of
the panel of cell lines, with one cell line per cancer type. RPPA is a high-throughput
analysis evaluating the levels of a panel of antibodies on protein expression in control
and intervention groups. In this context, control and IACS-13743 treated cell lines
were submitted for analysis to evaluate the impacts of the compound at the protein
level. The cell lines used were the U251 brain cancer cell line, AsPC-1 pancreatic
cancer cell line, and the AGS gastric cell line. Control and treatment samples were
done in triplicate and were stained for 486 unique antibodies, which were analyzed
by Array-Pro Analyzer 6.3 then by SuperCurve_1.5.0 via SuperCurveGUI_2.1.1. The
results from this analysis were first displayed volcano plots, to evaluate differentially
expressed genes and the degree to which they differed via fold change (Figure 22).
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U251 - Brain

AsPC-1 - Pancreas

AGS - Stomach

Figure 22. Volcano plots displaying proteomics data from Reverse Phase Protein Array (RPPA)
for the U251 brain cancer cell line. Horizontal red line is statistical significance at –log10(.05), log10(.005), -log10(.0005). Vertical lines indicate fold change: FCH=-1.5 and FCH=1.5, so +/log2(1.5) = +/-0.58496.
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Upon further analysis and ranking of the fold changes in the differentially
expressed genes according to the adjusted p-value, many of the proteins on the
PI3K/AKT pathway were significantly dysregulated in the tested cell lines (Figure 23);
most notably, all of the relevant antibodies targeting proteins on this pathway were
downregulated in the U251 brain cancer cell line, with ten of the twelve proteins
showing significant downregulation at p < 0.01 (Figure 23A).
When evaluating the tumor types, AKT2 was the only protein found to be
significantly downregulated in brain cancer, gastric cancer and pancreatic cancer,
after treatment with IACS-13743, indicating a potential direction of further research.
Differential expression was seen for almost all other proteins tested along this
pathway among the three cancer types.
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Figure 23. Proteins on the PI3K/AKT pathway and the degree of dysregulation
according to cancer type. A. U251 brain cancer cell line. B. AsPC-1 pancreatic
cancer cell line. C. AGS gastric cancer cell line. * indicates p < 0.05, ** indicates p <
0.01, *** indicates p < 0.001 and *** indicates p < 0.0001.
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The PI3K/AKT pathway is known to be one of the most oncogenic, and
operates in a complex and dynamic way. PI3K is upstream of AKT, which is upstream
of mTOR, so intervention at any phase of this pathway will yield varying outcomes
(Figure 24). Looking at the data, there is significant dysregulation seen at one of the
phosphorylated forms of PI3K, which could yield all of the effects that are seen in this
data downstream. Interestingly, with gastric cancer, none of the forms of PI3K are
dysregulated and appear to not have been affected by the treatment, though impacts
on AKT and mTOR are seen, so for this cancer type it is possible the effect is PI3Kindependent and occurs further downstream on the pathway than that of brain cancer.
With pancreatic cancer, there is a different relationship overall, as not only is there
not downregulation at the PI3K
point,

there

is

upregulation.

A

number of the AKT forms show
downregulation,

but

there’s

no

discernable relationship between
the downregulation of AKT and the
upregulation of mTOR, indicating
that while this form of pancreatic
cancer does yield dysregulation in
this

pathway,

supplemented

it

may
by

do

so

another

Figure 24: Schematic of PI3K/AKT pathway

mechanism.
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As an additional interesting finding, the proteomics results found PTEN
expressed differentially across the cancer types as a result of IACS-13743 (Figure
25). As it is an experimentally validated target of miR-10b, the expectation would be
that when oncomiR-10b is overexpressed, it binds the tumor suppressor gene,
causing it to be downregulated and impacting its regular function, leading to an
oncogenic outcome. Administration of the therapeutic compound would then lead to
increased binding to the overexpressed oncogenic miRNA of interest, leading to
restored mechanism of action of the target gene, bringing back its function. However,
this effect only appeared to be the case in the brain tumor cell lines that were tested
(LN229 and U251). A significant increase was seen, providing evidence indicating
that this compound had inhibited the oncogenic miRNA, restoring the function of the
tumor suppressor gene and thereby supporting the PI3K/AKT pathway suppression
data from the RPPA analysis. There are several reasons why this effect is not seen
throughout the screened cell line panel, primarily that the pathway through which miR10b and IACS-13743 interact through the AKT pathway could be PTEN-dependent
in some cancer tissue types and not others, as in this study, in the gastric cancer cell
line and in the pancreatic cancer cell line. This is supported through the literature
where there are mechanisms linking miR-10b to AKT via other pathways17, 27
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Figure 25: PTEN expression in the three cancer types. This data indicates a cell-type
dependent response to IACS-13743 and the further direction of finding tissue-specific
targets in these cancer types. * indicates p < 0.05, ** indicates p < 0.01.
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Western blot experiments were conducted to investigate these effects on
identified target genes in our two brain cancer cell lines (Figure 26). As expected, the
results were found to be consistent with what was found within the proteomics
analysis. As they are found to be the primary targets in the mechanistic pathway of
the parent compound linifanib, the protein expression of VEGF and PDGF were
evaluated after treatment with IACS-13743 via Western blot to determine their levels
as shown in Figure 26. In U251 and LN229, there seems to be little to no impact of
the compound on the expression level of these two targets, indicating that for these
cell lines, it leads credence to the theory that the drug is operating via the miRNA and
not necessarily via the kinases, or at the very least, it is working via a combination of
the two. Further investigation and validation would need to be conducted via kinome
screening to confirm with more certainty whether or not the kinases activated when
using this compound, and if so, whether this effect is cell or context-specific.
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Figure 26. A. Western blot of PTEN expression, a validated target of miR-10b,
and VEGF and PDGF expression, the target kinases of the parent compound.

As the PI3K/AKT pathway has long been established to be oncogenic96-98, the
findings indicate a potential mechanistic link between the inhibition of miR-10b and
the downstream genes in this pathway. This mechanism remains to be elucidated
and would require further analysis, as the two have a direct relationship, whereas
miRNAs operate via targeting, which would require an inverse relationship. One
approach is to computationally interrogate the pathways to determine which genes
appear to play important roles in this relationship. When preparing the data for
analysis, the log2 fold change of the data was calculated and the adjusted p-value
was used for analysis. Gene symbols were converted using the DAVID bioinformatics
resource99, 100 and the clusterProfiler data visualization and analysis package was
also used74. Pathway enrichment analysis was conducted on the significantly
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dysregulated genes in the U251 brain cancer cell line, the line in the cancer cell panel
with the greatest expression of miR-10b, and using the Hallmark gene set, it was
found that “Apoptosis” was the pathway most implicated in this change, along with
involvement of the “PI3K-AKT-MTOR1 signaling” pathway (Figure 27). The “G2M
checkpoint” was also implicated, which supports the cell cycle analysis in vitro data
presented earlier, although further investigation into the specific genes and potential
feedback mechanisms yielding this effect is needed. In addition, the “MTORC1
signaling” pathway is found to be negatively enriched, which is consistent with what
is expected given these findings. Investigating functional enrichment via Gene
Ontology yielded similar results, with “regulation of apoptotic signaling” as one of the
primary responses when evaluating the Biological Processes dataset (Figure 27B).
The results in the U251 brain cancer cell line were compared with those taken from
the AGS gastric cancer cell line (Figure 28), and from the Gene Ontology results it is
seen that apoptosis continues to be a primary hit, with “regulation of apoptotic
pathway” and “intrinsic apoptotic signaling pathway” within the top five results when
investigating the Biological Processes dataset, which a high level of significance
(Figure 26B). When interrogating the Hallmark gene set, “Apoptosis” was also the top
hit, along with involvement of the “PI3K-AKT-MTOR1 signaling” pathway, indicating
that while there are tissue and/or cancer specific effects of this compound on eventual
gene expression, ultimately both cancer types are implicating similar mechanistic
pathways.
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A

B

Figure 27: Pathway enrichment analysis of differentially expressed genes after Reverse
Phase Protein Array (RPPA) in the U251 brain cancer cell line. A. Gene Set Enrichment
Analysis from the MSigDB database. B. Pathway enrichment analysis using Gene
Ontology (GO). GeneRatio refers to the ratio of differentially expressed genes and
p.adjust refers to p-values adjusted for the false discovery rate (FDR) using the
Benjamin-Hochberg correction
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Figure 28: Pathway enrichment analysis of differentially expressed genes after Reverse
Phase Protein Array (RPPA) in the AGS gastric cancer cell line. A. Gene Set Enrichment
Analysis from the MSigDB database from the Broad Institute. B. Pathway enrichment
analysis using Gene Ontology (GO). GeneRatio refers to the ratio of differentially expressed
genes and p.adjust refers to p-values adjusted for the false discovery rate (FDR) using the
Benjamin-Hochberg correction
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Chapter 4. Discussion
Cancer continues to lead as one of the most prevalent health problems
globally. While advances have been made, it is becoming increasingly clear that there
are no cure-all forms of therapy and that successful treatment of these malignancies
will require more tailored and personalized approaches. To that end, in this work, a
novel small molecule is characterized against a unique oncogenic driver of cancer,
miRNA-10b. This compound has been found both to directly bind and inhibit this
miRNA, along with yielding potent anti-tumor effects.
While it is has long established that miR-10b functions in an oncogenic
manner, there have been varied proposed mechanisms as to how it operates in
recent years. Early studies implicated miR-10b in the promotion of cell migration,
invasion, and angiogenesis when it is overexpressed14, 19. However, other studies
have considered the dysregulation of the mechanisms of cellular apoptosis and cell
cycle arrests13, which ultimately the data supports. Six cancer cell lines from three
malignant cancer cell types with varying expression levels of miR-10b were used for
the in vitro analyses of this work, namely cancer cell lines from brain, pancreas and
stomach. Advanced cancers from these tissues are known to generally be resistant
to common treatment modalities and alternative approaches to target oncogenic
biomarkers are critically needed101-103.
Brain cancer was used as the cell line of interest in the cerebral organoid
model, as it has been established in the literature that in the context of the brain
microenvironment, while a baseline expression of miR-10b has generally not been
found in amounts in normal brain cells, miR-10b has been found to be highly
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overexpressed in several malignant primary brain tumor types3,

18-20

. Therefore,

adding this cancer cell type to this more advanced in vitro model more closely
recapitulates what occurs in a clinical setting.
The data has confirmed that the compound IACS-13743 directly inhibits miR10b and yields anti-tumor effects through apoptosis and cell cycle arrest at the G2/M
phase in a brain tumor cell line model. Apoptosis is established as the mechanism for
programmed cell death and is a known hallmark of cancer, where cancer cells are
able to evade apoptotic mechanisms to continue proliferating abnormally104. The
discovery and development of clinical agents that are able to modulate apoptosis are
integral to the treatment of cancer as they would allow for the abnormal cells to
undergo appropriate cell death, be highly effective and allow for the cancer to be
treated in a mechanistic way by the cells. The G2/M phase is a cell cycle checkpoint
that operates via modulating whether sustained DNA damage is significant enough
to delay the process in order to undergo DNA repair, or if the damage is too severe
and must induce apoptosis105. The results suggest that cell cycle arrest is found at
G2/M, indicating that there is a degree of DNA damage induced by IACS-13743 that
is insurmountable against the tumor cells, leading the cells to continue to apoptosis.
This is further supported by the proteomics results using high-throughput ReversePhase Protein Array (RPPA) and computational pathway enrichment analysis, where
in two databases, the Hallmark Gene Set in GSEA and Gene Ontology, apoptosis
was detected as one of the top hits of the pathways implicated by this compound in
two of the cancer cell types. Additionally, the RPPA results revealed downregulation
after IACS-13743 treatment in many of the key proteins implicated in the PI3K/AKT
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pathway. As this pathway has long been established to be oncogenic and an
attractive target for cancer drug discovery due to its predisposition to aberration in
cancer96-98, this provides an interesting future direction for further investigation. More
specifically, given the data, the isoform AKT2 is significantly downregulated in all
three of the cancer types from three varied tissues, which provides a potential
biomarker for further investigation and therapeutic targeting. Overall, these results of
this study support a mechanistic link between miR-10b and the genes of this pathway,
the exact link of which remains to be elucidated.
A common challenge within miRNA research is that direct binding of the
sequence and target can be challenging to confirm for a number of reasons. These
reasons can be the size of the sequence, which for miRNAs is known to be very short,
on the order of 18-22 nucleotides, or the overall solubility of the compound. For the
compound linifanib, the parent compound found in a screening of a small molecule
library to target miR-10b in the first phase of this study56, its efficacy was established
in vitro and in vivo, but due to the lack of thorough solubility of the molecule in solution,
there was no ability to confirm whether there was direct binding between the miRNA
and the compound. Therefore, any conclusions as to the effect of the compound on
tumor cells can only be correlations, with no confirmation of causation.
However, in this work, direct binding of IACS-13743 and miR-10b was
confirmed via robust NMR studies. When overlaying the NMR spectra generated
when combining the novel compound and the sequence of the miRNA, a decrease in
the NMR peak signal was shown and line broadening was seen, which is indicative
of direct binding of the two elements. The proposed region on the molecule where
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binding occurs has also been computationally modeled, shown as a 3D
reconstruction in Figure 16C, providing information that will be instrumental for further
structural derivations of this compound and the development of small compounds
against other oncogenic miRNAs. As stated earlier, the same experiments yielded no
effect in the parent compound.
To additionally validate that this direct binding exists and that the mechanism
of this compound is working through the oncogenic miRNA, an in-house kinase assay
for detection of enzymatic activity was conducted. The results showed that while
IACS-13743 does act at a low nanomolar level towards certain kinases, the values at
which it acts is an order of magnitude less potent than that of the parent compound
linifanib. This is promising, as this provides evidence that this novel compound
doesn’t primarily operate via kinase pathway, and could thus be working via inhibition
of miR-10b. Alternatively, the decrease in potency with the kinases it could mean the
compound is operating via both pathways, kinases and miRNA. Linifanib is a potent
kinase inhibitor and low nanomolar activity is expected, however, it is promising that
while the derivative compound acts on the same kinases, it acts upon them to a lesser
degree. It is known from the direct binding studies that this oncogenic miRNA is being
targeted and inhibited via IACS-13743, and that key signaling pathways in cancer are
also being activated. This opens the door for the evaluation of whether this compound
can remain potent in acting against malignant cells when mechanisms of treatment
resistance arise via kinase signaling pathways in specific cancer types. The response
to this compound has also been found to be cell type and context dependent, thus if
the ratio of how this compound operates towards these distinct oncogenic elements
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is evaluated, it may provide more information to stratify its administration to maximize
impact to patients who have these cancers, and are identified to have overexpression
of this miRNA. While the results are promising, they are preliminary, and a full-scale,
high-throughput kinase screening is planned to further and conclusively validate the
degree through which the compound is working through the miR-10b pathway and
target kinases.
This study is the first of its kind in investigating small molecule inhibitors of
miRNAs in organoids. As previously mentioned, organoids are 3D cultures of humanderived cells that are able to develop into tissues that are structurally and
phenotypically similar to the origin organ of interest. When cultivated and grown, they
can be used in cancer research to bridge the gap between in vitro, in vivo, and clinical
studies in humans and represent the tissue and tumor microenvironment in which
tumors are growing and proliferating49, 53. Evaluating endogenous levels of miR-10b
in the cerebral organoid model has supported what has been reported in the current
literature, that the expression of miR-10b is low and nearly undetectable in normal
brain tissue. This is further shown in the in-situ hybridization experiment that was
conducted, where the control group containing organoids with no tumor involvement
had very low to no miR-10b expression detected (Figure 20). Co-culturing with brain
cancer cell lines known to contain high levels of miR-10b increased the expression
level of this oncogenic miRNA as detected by qRT-PCR, establishing that the cancer
cell lines successfully invaded the organoid and thereby providing a solid therapeutic
model through which this, or any other therapeutic downstream, can be tested. The
novel compound IACS-13743 was then evaluated on both cell lines co-cultured with
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the organoids using two doses and it was found that there was a significant decrease
of the expression of miR-10b at 10µM, indicating that even in a more advanced
model, the results of the in vitro studies as to the efficacy of the compound are
confirmed. One aspect to consider with the evaluation of these results is that the
organoids are a system that do not contain a vasculature, so while the compound
mechanism and function is valuable information to assess, the cerebral organoids do
not have an inherent blood-brain barrier, so further research will need to be conducted
to ensure that it does operate and permeate well throughout the BBB in a functional
in vivo context and later in a clinical context. Nevertheless, these results are
promising as to the establishment of this model, through which to date only glioma
stem cells (GSCs) have been successful in developing, and using well-designed
therapeutics to evaluate effects down the line. This work has validated existing
knowledge that endogenous neural tissue expresses low miR-10b, and that in a
cancer context, the level of miR-10b in the brain increases due to the presence of
tumor. It has also introduced confirmatory data that this small molecule yields
significant anti-tumor effects in this model.
These findings provide evidence for using a small molecule inhibitor of an
oncogenic miRNA in an in vitro and cerebral organoid context. Furthermore, antitumor effects in these models have been characterized against a panel of cancer cell
lines and have further confirmed the oncogenic role of this miRNA in various tumor
types. While a potential mechanistic link between miR-10b and dysregulation of the
PI3K/AKT pathway has been proposed, the role of miR-10b has been found to be
both cell type and context dependent, and ultimately the anti-tumor effects that are
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reported will depend on a multitude of factors and require even further rigorous
characterization when evaluated in individual cancer types. While there is optimism
about further downstream analyses, it is kept in mind that cancer is a highly dynamic
and complex disease, and while this compound isn’t proposed as a sole cure for these
cancer types, the goal is to present a methodology in drug design and development
that can take what has been established and apply it in innovative ways, that can
target oncogenic mechanisms. These drugs can then either be used independently
or in conjunction with existing therapeutic modalities and to target malignancies with
unique biomarkers in patients that may be more receptive to these treatments.
Moving forward with this compound or other therapeutic approaches will necessitate
needing to keep these aspects in mind.
To conclude, it has become more important to move towards more
personalized therapeutic approaches as more is learned about the compositions of
malignant and heterogeneous cancers. Using existing compound libraries that have
already been FDA-approved and tested for human safety to identify clinical agents
that target oncogenic miRNAs presents the opportunity for identification of novel
biomarkers and directions of study, along with the development of innovative
therapeutic approaches that significantly lessen the bench-to-bedside process and
allow for more robust and expedient development of therapeutics for patients. The
findings in this study highlight the IACS-13743 as an inhibitor of oncogenic miR-10b
via the PI3K/AKT pathway in multiple malignant cancer types.
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Chapter 5. Future Directions
The long-term goal of this work is to further develop a novel therapeutic
compound derived from an established FDA-approved and clinically tested agent,
that was found to inhibit the oncogenic driver miR-10b and can move forward to
clinical applicability. This work provides a foundational step from the perspectives of
medicinal chemistry, structural biology, molecular biology and cancer therapeutics.
While these results have been encouraging, more research is needed to further
optimize the design and development of this clinical agent with the potency and
efficacy to yield significant therapeutic benefit to patients with cancer. Ultimately, this
may require analysis and development of a tertiary chemical library with structures
that have increased specificity, affinity and sensitivity to the target of interest, in this
case, miR-10b. These modifications will further strengthen the relationship between
the compound and miRNA direct binding that was found in this work. Now that direct
binding yielding miRNA inhibition was established, it provides evidence and solid
backing for the anti-tumor effects that were shown. In a more generalizable manner,
this study provides a framework through which future compound libraries can be
interrogated in order to test compounds and their affinities for known oncogenic
drivers. There is still much to learn about the interplay of cancer elements, but with
the identification of miRNAs that can impact gene expression pre and posttranscriptionally yielding oncogenic outcomes, this opens the door to utilizing more
molecules to target these aberrant elements and ultimately design more specific and
impactful targeted therapeutics. The compounds can not only stand alone, but work
with our existing therapeutics to yield greater impact.
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Combination therapies have been found to yield greater efficacy in many
contexts, particularly in cancer therapy106, 107, where there is such heterogeneity of
tumor and tissue types that it becomes apparent that there are no true standard
treatment regimens. A potential therapeutic direction moving forward is the
introduction of small molecule compounds as adjuvant agents to be administered with
conventional therapies such as chemotherapy and radiation. Given their chemical
and physical properties when it comes to size and permeability, these agents may
not only operate in isolation, but further enhance response of these existing
modalities. For instance, in the work by Zhen et al., the authors found overexpressed
miR-10b to be associated with increased treatment resistance to radiation in
glioblastoma via the PI3K/AKT pathway108. Given the results with IACS-13743, there
is the high applicability and potential for further research and advances in that domain
to applying an anti-miR-10b therapeutic in conjunction with radiation therapy for a
subset of patients. Additionally, there has been work from the systems biology
perspective investigating the concept of cooperative miRNAs, where miRNAs work
together to operate through the targeting of a similar pathway, as a supplemental
therapeutic avenue for combination therapy109.
Another potential opportunity for exploration is investigating closely related
miRNAs. As previously mentioned, this specific microRNA is part of the highly
conserved miR-10 family, composed of both miR-10a and miR-10b. For these two
miRNAs, their respective nucleotide sequences differ by only one nucleotide base.
Theoretically, given their sequences, these two miRNAs should yield very similar, if
not identical, targets given how close they are structurally110. However, while miR-
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10b has consistently been found to be dysregulated and most commonly upregulated
in a number of cancer types, there is some inconsistency as to how miR-10a presents
in cancer, where miR-10a does not tend to yield the same oncogenic outcomes, at
the very least not in the same cancer types. Given their near similarity, it would be
enlightening to investigate further, especially from the therapeutic perspective, to
assess the differences in the binding to their target genes, and how molecules bind
their sequences, to determine whether this work may yield any additional benefit to
indications and conditions where miR-10a is dysregulated.
As another potential research direction, there are various limitations in the lack
of reliable biomarkers that allow for accurate diagnosis and treatment response to
current therapeutic modalities. Earlier, the use of biomedical imaging was discussed
and its powerful impact on evaluating morphology and volumes, along with treatment
response of established tumors. In terms of early detection and longitudinal
assessment, while imaging is a powerful tool, it is not always the most accessible and
feasible to conduct.
As oncogenic miRNAs are becoming more established as biomarkers for
cancer, determining novel and alternative methods to measure miRNA levels in the
human body could be useful for early diagnosis and prognostics. For instance, in the
work by Huang et al. (2016), they identified a panel of miRNAs, with miR-10b
included, as a diagnostic signature for gastric cancer using serum from patients111.
Additionally, cerebrospinal fluid (CSF) in the brain is commonly used as a source for
diagnosis for a multitude of neurological diseases; its use as a biomarker for
circulating miRNAs has a great potential for clinical relevance when differentiating
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between primary and metastatic lesions and when access to the tumor is difficult or
compromised in the brain, as discussed earlier112, 113. In fact, in a study by Teplyuk et
al., (2012), the authors linked a series of miRNAs, with miR-10b included, with the
presence or primary and metastatic brain tumors114. As access to CSF is more readily
available than a biopsy, this allows for the opportunity of longitudinal monitoring of
levels as an indicator of malignancy, in addition to other modalities such as advanced
non-invasive imaging.
Overall, this study serves as a fundamental step forward in characterizing a
novel small molecule compound that can inhibit a known oncogenic biomarker in
multiple cancer types. As more is learned about the complexity of cancer, it is
important to continue to tailor therapeutic advances. Taking from sources in the form
of FDA-approved molecules and established chemical libraries and applying them in
varied oncogenic contexts will save cost, time and inevitably the lives of many as the
work is advanced with new and current knowledge to ultimately help end cancer.
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